Baltimore Sun, Black Enterprise, TMCnet.com

If Alba Therapeutics Corp. didn’t have product protection for the 200 patents it has either applied for or been issued, the Baltimore biotech might be $300 million poorer, according to news reports. Speaking from his office at the new UMBioPark, Blake Paterson, MD, Alba’s chief executive officer and co-founder, said, “If you're making that sort of investment, and taking that degree of risk, you need to have a patent on that product. ... It’s fundamental.”